CRISPR Tech Cuts LDL Cholesterol for 18 Months in Primate Trials
Scribe Therapeutics shows preclinical CRISPR platforms that durably lower LDL cholesterol for nearly 18 months with minimal off-target effects.
Summary
Scribe Therapeutics has unveiled two engineered CRISPR platforms — ELXR and XE — aimed at treating high LDL cholesterol, a major cardiovascular risk factor. In animal studies, their lead program STX-1150 kept LDL cholesterol suppressed for nearly 18 months using a single treatment. The ELXR system works by silencing the PCSK9 gene, which normally limits the body's ability to clear bad cholesterol, while achieving up to 100-fold fewer unintended genetic changes compared to earlier approaches. The XE genome editor showed complete, saturating edits in primate livers with no detectable off-target effects. An AI tool called DeepXE also cuts the time needed to design these treatments by about half. These results are preclinical but suggest a potential one-time gene-based alternative to daily cholesterol medications.
Detailed Summary
High LDL cholesterol remains one of the most significant and modifiable risk factors for heart disease, the leading cause of death globally. Current treatments like statins require lifelong daily dosing and work imperfectly for many patients. Scribe Therapeutics is developing gene-based tools that could offer a durable, one-time solution by permanently silencing or editing the gene responsible for elevated LDL.
At the ASGCT 2026 meeting, Scribe presented preclinical data on two platforms: ELXR, an epigenetic silencer, and XE, a genome editor derived from an engineered version of CasX. ELXR targets the PCSK9 gene using a novel locking mechanism that activates only at the intended DNA site, improving precision. The company reported at least fourfold better on-target gene repression and a 10- to 100-fold reduction in unintended transcriptional effects compared to earlier designs.
The XE editor demonstrated complete, saturating liver edits across multiple genetic targets in non-human primates, with no detectable off-target editing in human liver cells even at high doses. Most strikingly, their lead drug candidate STX-1150 maintained significantly reduced LDL cholesterol levels in primates for nearly 18 months following a single treatment — suggesting the effect could be long-lasting or even permanent.
Scribe also introduced DeepXE, an AI model that reduces the burden of selecting the right genetic guide sequences by approximately 50%, accelerating development timelines. Together, these tools form a pipeline designed to translate into the clinic with greater safety and efficiency.
Important caveats apply: all data presented are preclinical, meaning results in animals do not guarantee the same outcomes in humans. No human trials have been reported yet. Regulatory approval remains years away, and long-term safety of permanent gene silencing is still under evaluation. Nonetheless, for the millions at cardiovascular risk, this platform represents a potentially transformative direction.
Key Findings
- STX-1150 maintained LDL cholesterol reduction for nearly 18 months in primates after a single treatment.
- ELXR silencer achieved fourfold better on-target repression with 10–100x fewer off-target transcriptional effects.
- XE genome editor showed complete liver editing in primates with no detectable off-target effects in human hepatocytes.
- AI tool DeepXE cuts guide RNA selection workload by ~50%, accelerating drug design with under 10% false-negative rate.
- PCSK9 gene silencing via CRISPR may offer a one-time alternative to daily LDL-lowering medications like statins.
Methodology
This is a news report summarizing preclinical data presented at ASGCT 2026 by Scribe Therapeutics. Evidence is based on company-reported conference presentations, not yet peer-reviewed publications. Source is Longevity.Technology, a credible longevity-focused outlet, but independent verification of the data is not yet possible.
Study Limitations
All findings are preclinical and derived from non-human primate and cell studies; human efficacy and safety are unconfirmed. Data were presented at a conference and have not been peer-reviewed or published in a journal. Long-term safety of permanent epigenetic gene silencing in humans remains unknown and warrants close scrutiny.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.